BPC-157 vs PEG-MGF

BPC-157 and PEG-MGF are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.

BPC-157 is a synthetic 15-amino-acid peptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1419.5 g/mol) derived from a protein found in human gastric juice. It has demonstrated robust regenerative and cytoprotective effects across hundreds of animal studies spanning tendon, ligament, muscle, bone, nerve, GI tract, and blood vessel healing. However, human clinical data is extremely limited — only three pilot studies have examined BPC-157 in humans as of 2025 (knee pain n=16, interstitial cystitis n=12, IV safety n=2). The FDA classifies it as Category 2, prohibiting compounding, and WADA bans its use in sports.

Key claims: Accelerates tendon and ligament healing; Heals gut lining and treats leaky gut; Reverses NSAID-induced GI damage.

PEG-MGF (Pegylated Mechano Growth Factor) is a synthetic, PEGylated form of the C-terminal peptide of mechano growth factor (MGF), a splice variant of the IGF-1 gene (IGF-1Ec in humans, IGF-1Eb in rodents). Native MGF is expressed locally in skeletal muscle immediately following mechanical overload or damage (e.g., resistance exercise). It stimulates muscle satellite cell (stem cell) activation and proliferation, initiating the early repair response before the sustained IGF-1Ea isoform takes over for differentiation. Because native MGF has an extremely short half-life (minutes), PEGylation (conjugation with polyethylene glycol) protects the peptide from enzymatic degradation, extending systemic circulation. It is prohibited by WADA and not approved for human therapeutic use.

Key claims: Activates muscle satellite cells for repair; Promotes muscle hypertrophy; PEGylation extends duration of action.

Both peptides are studied for: Injury Recovery.

BPC-157 is also researched for: Gut Health.

PEG-MGF is also researched for: Body Composition.

BPC-157: No completed randomized controlled human clinical trials for safety assessment Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology FDA previously classified BPC-157 as Category 2 (significant safety concerns); removed from Category 2 on April 15, 2026. PCAC review pending July 2026 to determine compounding eligibility. FDA noted insufficient human safety data and potential immunogenicity risks.

PEG-MGF: No human clinical trials — safety profile is entirely unknown No formal toxicology studies published for PEG-MGF Theoretical oncogenic risk: satellite cell proliferation and IGF-1 pathway activation are relevant to cancer biology